Web sitemizi kullanabilmek için javascript özelliğini etkinleştirmeniz gerekmektedir.

MLP Care (MPARK) 3Q26 Financial Results

Tacirler Investment

We view the company's 3Q26 financial results as slightly positive, driven by revenues broadly in line with market expectations, stronger-than-expected EBITDA and improving operational margins. We believe new hospital investments and strong cash generation support the company's medium-term growth outlook. MLP Saglik remains in our model portfolio with a 12-month target price of TL645 per share and a BUY recommendation.

Detailed PDF   -   308 KB

Disclaimer

Your transaction is being processed. Please wait.